

Supplemental Tables

Supplemental table S1: Univariate analysis of association of clinical variables

Variable	CC	p-value
Sputum Eosinophils (log, percentage)	0.27	0.0007
Exacerbations (no, one, > one)	0.25	0.0060
Exhaled NO (log concentration, ppm)	0.20	0.0104
Blood Eosinophils (log, absolute numbers)	0.14	0.0704
Gender (m/f)	0.14	0.0709
disease duration (log years)	0.14	0.0862
Cummulative sIgE (log sum)	0.08	n.s.
Age (years)	0.06	n.s.
Number of sensitisations	0.05	n.s.
Atopy (y/n)	-0.03	n.s.
Systemic Corticosteroids (y/n)	0.03	n.s.
Smoking packyears (log years)	-0.05	n.s.
Fluticasone Equivalent (log dose, mg)	0.00	n.s.

CC =pairwise correlation coefficient; Exhaled NO = exhaled nitric oxide;

Supplemental table S2: Summary of Linear Regression Model:

Variable	Estimate	SE	t Ratio	p-value
Gender (m/f)	0.769	0.208	3.71	0.0006*
disease duration (log years)	0.412	0.111	3.7	0.0006*
Exhaled NO (log concentration, ppm)	0.473	0.146	3.25	0.0023*
Atopy (y/n)	0.832	0.300	2.78	0.0083*
Systemic Corticosteroids (y/n)	0.597	0.309	1.94	0.0599
Smoking packyears (log years)	0.111	0.099	1.12	0.2696
Sputum Eosinophils (log, percentage)	0.020	0.022	0.9	0.3746
Age (years)	0.002	0.009	0.2	0.8458
Intercept	-0.100	1.262	-0.08	0.9373
Fluticasone Equivalent (log dose, mg)	-0.004	0.152	-0.03	0.9799

*indicates significant variable in linear regression model. SE = standard error of estimate;

Linear regression model characteristics: $r^2=0.51$, $p=0.0002$. Exhaled NO = exhaled nitric oxide; Estimates indicate direction and quantity of effect size.

Supplemental table S3: Cystic Fibrosis Patients with and without allergic broncho-pulmonary aspergillosis:

Cystic Fibrosis	Allergic Broncho-Pulmonary Aspergillosis	
	Yes	No
N	9	14
Women (%)	66	43
Age (years)	18.07 (7.93)*	9.94 (9.94)
FEV1% pred	61.89 (25.94)**	97.5 (14.68)
IgE (IU/mL)	1481 (1246)***	36 (50.83)
Highest IgE (IU/mL)	2394 (1433)****	83 (137)

N = number, FEV1% = Forced expiratory volume in 1 second (percentage of predicted); IgE = total serum IgE; BMI = body mass index; ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 (yes vs. no; value in brackets are standard deviations).

Supplemental table S4: C4Ma3 baseline levels predict therapy response type:

Responder Type	Responder	Non-Responder
N	10	9
Predicted Responder	9	2
Predicted Non-Responder	1	7
Specificity	0.90	95% CI: 0.60 to 0.98
Sensitivity	0.78	95% CI: 0.45 to 0.94
DOR	31.5	95% CI: 2.35 to 422.30

DOR: Diagnostic Odds Ratio.